![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 11-Apr-2012[ | E-mail |
Share ] Contact: Fintan R. Steele, Ph.D.
fsteele@somalogic.com
720-214-3080
SomaLogic, Inc.
SOMAscan technology identifies significant protein expression level differences in tumors vs. adjacent non-cancerous tissue, confirming known biomarkers and discovering new ones
Boulder, CO April 11, 2012 -- In a scientific paper published today in the journal PLoS ONE, researchers from SomaLogic and the University of Washington in Seattle describe the first application of the SOMAscanTM proteomic assay technology to tissue samples. Working with both tumor and non-cancerous lung samples from patients with non-small cell lung cancer (NSCLC), they identified significant expression changes in 36 proteins, including 13 proteins not previously associated with the disease. These findings reveal significant new information about the biology underlying NSCLC, and have implications for improving early diagnosis and treatment.
"Early detection of NSCLC can dramatically improve the prognosis for patients with the disease, as has been shown recently through the use of CT-scans in a high-risk population of heavy smokers," said Sheri Wilcox, Ph.D., Director of Discovery Sciences at SomaLogic. "However, this approach has a high false-positive rate, which can result in overdiagnosis and unnecessary treatment. We set out to find additional molecular 'biomarkers' that would help guide both the use of imaging techniques as well as choosing appropriate treatments."
In their study, the researchers found 36 protein biomarkers that showed significant expression differences between the tumor tissue and non-cancerous lung tissue samples taken from the same patients. These potential biomarkers were discovered by simultaneously measuring the expression levels of 820 different proteins in all samples examined, using SomaLogic's SOMAscan proteomic assay. Of these 36 potential biomarkers, thirteen had not previously been associated with NSCLC, providing new biological insights into the disease as well as suggesting potential new therapeutic targets.
In addition to the NSCLC protein biomarker discovery, the scientists also demonstrate the utility of the protein-binding reagents used in SOMAscan for direct visualization of protein expression in tissue sections using standard histopathology techniques. SOMAmer (Slow Off-rate Modified Aptamer) binding reagents bind their respective proteins in a manner similar toand as effective asantibodies, but unlike antibodies they can be used in highly multiplexed applications to look at expression differences across thousands of proteins in a single experiment. And as demonstrated in the PLoS ONE paper, SOMAmers can also be used as individual tissue probing agents for pathology studies.
###
The paper is available at http://dx.plos.org/10.1371/journal.pone.0035157.
About SomaLogic
SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colorado. The company's mission is to use its proprietary proteomic technology to develop enhanced protein analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of healthcare by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.
About SOMAscan/SOMAmer
SomaLogic's proprietary SOMAscan proteomic technology platform underlies a rapidly growing number of new diagnostic and therapeutic opportunities. The power of the SOMAscan platform comes from its use of a new generation of nucleic acid-based protein-binding reagents, called SOMAmer (Slow Off-rate Modified Aptamer) reagents. The unique physical properties of SOMAmers empower the accurate detection and measurement of greater than one thousand proteins to date over a large range of concentrations in a small volume of sample, all in a single SOMAscan assay.
Contact
Fintan R. Steele, Ph.D.
Executive Director of Communications
SomaLogic, Inc.
Phone: 720-214-3080
Email: fsteele@somalogic.com
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 11-Apr-2012[ | E-mail |
Share ] Contact: Fintan R. Steele, Ph.D.
fsteele@somalogic.com
720-214-3080
SomaLogic, Inc.
SOMAscan technology identifies significant protein expression level differences in tumors vs. adjacent non-cancerous tissue, confirming known biomarkers and discovering new ones
Boulder, CO April 11, 2012 -- In a scientific paper published today in the journal PLoS ONE, researchers from SomaLogic and the University of Washington in Seattle describe the first application of the SOMAscanTM proteomic assay technology to tissue samples. Working with both tumor and non-cancerous lung samples from patients with non-small cell lung cancer (NSCLC), they identified significant expression changes in 36 proteins, including 13 proteins not previously associated with the disease. These findings reveal significant new information about the biology underlying NSCLC, and have implications for improving early diagnosis and treatment.
"Early detection of NSCLC can dramatically improve the prognosis for patients with the disease, as has been shown recently through the use of CT-scans in a high-risk population of heavy smokers," said Sheri Wilcox, Ph.D., Director of Discovery Sciences at SomaLogic. "However, this approach has a high false-positive rate, which can result in overdiagnosis and unnecessary treatment. We set out to find additional molecular 'biomarkers' that would help guide both the use of imaging techniques as well as choosing appropriate treatments."
In their study, the researchers found 36 protein biomarkers that showed significant expression differences between the tumor tissue and non-cancerous lung tissue samples taken from the same patients. These potential biomarkers were discovered by simultaneously measuring the expression levels of 820 different proteins in all samples examined, using SomaLogic's SOMAscan proteomic assay. Of these 36 potential biomarkers, thirteen had not previously been associated with NSCLC, providing new biological insights into the disease as well as suggesting potential new therapeutic targets.
In addition to the NSCLC protein biomarker discovery, the scientists also demonstrate the utility of the protein-binding reagents used in SOMAscan for direct visualization of protein expression in tissue sections using standard histopathology techniques. SOMAmer (Slow Off-rate Modified Aptamer) binding reagents bind their respective proteins in a manner similar toand as effective asantibodies, but unlike antibodies they can be used in highly multiplexed applications to look at expression differences across thousands of proteins in a single experiment. And as demonstrated in the PLoS ONE paper, SOMAmers can also be used as individual tissue probing agents for pathology studies.
###
The paper is available at http://dx.plos.org/10.1371/journal.pone.0035157.
About SomaLogic
SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colorado. The company's mission is to use its proprietary proteomic technology to develop enhanced protein analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of healthcare by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.
About SOMAscan/SOMAmer
SomaLogic's proprietary SOMAscan proteomic technology platform underlies a rapidly growing number of new diagnostic and therapeutic opportunities. The power of the SOMAscan platform comes from its use of a new generation of nucleic acid-based protein-binding reagents, called SOMAmer (Slow Off-rate Modified Aptamer) reagents. The unique physical properties of SOMAmers empower the accurate detection and measurement of greater than one thousand proteins to date over a large range of concentrations in a small volume of sample, all in a single SOMAscan assay.
Contact
Fintan R. Steele, Ph.D.
Executive Director of Communications
SomaLogic, Inc.
Phone: 720-214-3080
Email: fsteele@somalogic.com
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
star jones evan longoria wheres my refund photo of whitney houston in casket carrot top george huguely whitney houston casket photo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.